Canadian Journal of Gastroenterology and Hepatology / 2019 / Article / Tab 1

Research Article

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy

Table 1

Characteristics of nonresponders to interferon-free therapy retreated with genotype specific DAA regimens, compared to the whole population of patients included in the EpiTer-2 database.

ParameterStudied population
n=31

females/males, n (%)16/15 (52%/48%)

Age [years], mean ± SD; min-max54 ± 11; 23-77

HCV genotype, n (%)
 1b23 (74%)
 33 (10%)
 45 (16%)

Fibrosis, n (%)
 F01 (3%)
 F13 (10%)
 F23 (10%)
 F32 (6%)
 F422 (71%)

Primary regimen, on schedule/discontinued, n (%)19/12 (61%/39%)
 OBV/PTV/r+DSV ± RBV, on schedule4 (13%)
 OBV/PTV/r+DSV ± RBV, discontinued11 (35%)
 LDV/SOF ± RBV, on schedule7 (23%)
 LDV/SOF ± RBV, discontinued0
 ASV+DCV, on schedule3 (10%)
 ASV+DCV, discontinued1 (3%)
 SOF+RBV, on schedule3 (10%)
 SOF+RBV, discontinued0
 Other SOF based†, on schedule2 (6%)
 Other SOF based†, discontinued0

History of primary regimen failure, n (%)
 Discontinued due to adverse events11 (35%)
 Relapse10 (32%)
 Non-response9 (29%)
 Other‡1 (3%)

Period between primary and rescue therapy [months], mean ± SD; min-max9.0 ± 5.0; 0-18

†SOF+SMV+RBV and SOF+DCV+RBV.
‡improper primary regimen discontinued after 4 weeks.
DAA: direct acting antivirals; SD: standard deviation; HCV: hepatitis C virus; F: fibrosis; OBV: ombitasvir; PTV: paritaprevir; DSV: dasabuvir; RBV: ribavirin; LDV: ledipasvir; SOF: sofosbuvir; ASV: asunaprevir; DCV: daclatasvir; SMV: simeprevir.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.